Johnson Investment Counsel’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.41M Sell
100,100
-5,581
-5% -$146K 0.02% 298
2026
Q1
$2.97M Sell
105,681
-8,460
-7% -$225K 0.02% 255
2025
Q4
$2.84M Sell
114,141
-210
-0.2% -$5.3K 0.02% 247
2025
Q3
$2.91M Sell
114,351
-9,647
-8% -$238K 0.02% 241
2025
Q2
$3.01M Sell
123,998
-19,435
-14% -$453K 0.03% 224
2025
Q1
$3.63M Buy
143,433
+33,068
+30% +$865K 0.04% 201
2024
Q4
$2.93M Sell
110,365
-21,537
-16% -$584K 0.03% 225
2024
Q3
$3.82M Buy
131,902
+1,439
+1% +$42K 0.04% 189
2024
Q2
$3.65M Sell
130,463
-7,291
-5% -$201K 0.04% 184
2024
Q1
$3.82M Sell
137,754
-6,038
-4% -$168K 0.04% 179
2023
Q4
$4.14M Sell
143,792
-17,544
-11% -$530K 0.05% 168
2023
Q3
$5.35M Buy
161,336
+9,863
+7% +$349K 0.07% 138
2023
Q2
$5.56M Sell
151,473
-9,318
-6% -$363K 0.07% 138
2023
Q1
$6.56M Sell
160,791
-44,483
-22% -$1.92M 0.09% 126
2022
Q4
$10.5M Buy
205,274
+1,260
+0.6% +$60.4K 0.14% 99
2022
Q3
$8.93M Sell
204,014
-7,973
-4% -$387K 0.13% 98
2022
Q2
$11.1M Buy
211,987
+21,964
+12% +$1.12M 0.16% 93
2022
Q1
$9.84M Sell
190,023
-6,943
-4% -$360K 0.12% 109
2021
Q4
$11.6M Sell
196,966
-8,348
-4% -$414K 0.14% 99
2021
Q3
$8.83M Buy
205,314
+20,510
+11% +$909K 0.12% 112
2021
Q2
$7.24M Sell
184,804
-617
-0.3% -$24K 0.1% 115
2021
Q1
$6.72M Buy
185,421
+3,692
+2% +$131K 0.1% 120
2020
Q4
$6.69M Sell
181,729
-10,879
-6% -$399K 0.11% 107
2020
Q3
$6.71M Sell
192,608
-276
-0.1% -$9.68K 0.12% 106
2020
Q2
$5.98M Sell
192,884
-5,055
-3% -$172K 0.12% 106
2020
Q1
$6.13M Sell
197,939
-1,292
-0.6% -$44K 0.14% 102
2019
Q4
$7.41M Sell
199,231
-9,756
-5% -$348K 0.14% 107
2019
Q3
$7.12M Buy
208,987
+39,533
+23% +$1.44M 0.14% 105
2019
Q2
$6.96M Buy
169,454
+815
+0.5% +$32.4K 0.14% 108
2019
Q1
$6.79M Sell
168,639
-8,463
-5% -$339K 0.15% 104
2018
Q4
$7.33M Buy
177,102
+7,403
+4% +$307K 0.18% 96
2018
Q3
$7.09M Buy
169,699
+3,896
+2% +$150K 0.16% 103
2018
Q2
$5.71M Sell
165,803
-4,163
-2% -$142K 0.14% 107
2018
Q1
$5.72M Sell
169,966
-190
-0.1% -$6.53K 0.15% 105
2017
Q4
$5.85M Buy
170,156
+1,717
+1% +$58.5K 0.15% 108
2017
Q3
$5.71M Sell
168,439
-3,073
-2% -$98.8K 0.15% 108
2017
Q2
$5.46M Buy
171,512
+5,944
+4% +$187K 0.15% 106
2017
Q1
$5.37M Sell
165,568
-7,742
-4% -$244K 0.16% 105
2016
Q4
$5.34M Sell
173,310
-2,497
-1% -$76.2K 0.16% 104
2016
Q3
$5.65M Buy
175,807
+6,075
+4% +$203K 0.18% 98
2016
Q2
$5.67M Buy
169,732
+3,936
+2% +$126K 0.19% 97
2016
Q1
$4.66M Buy
165,796
+4,829
+3% +$138K 0.16% 101
2015
Q4
$4.93M Buy
160,967
+2,399
+2% +$75.5K 0.17% 97
2015
Q3
$4.72M Sell
158,568
-8,758
-5% -$281K 0.17% 99
2015
Q2
$5.32M Buy
167,326
+24,250
+17% +$790K 0.18% 99
2015
Q1
$4.72M Buy
143,076
+16,925
+13% +$538K 0.16% 102
2014
Q4
$3.73M Buy
126,151
+11,953
+10% +$343K 0.12% 118
2014
Q3
$3.2M Sell
114,198
-4,377
-4% -$123K 0.11% 122
2014
Q2
$3.34M Sell
118,575
-628
-0.5% -$17.9K 0.12% 107
2014
Q1
$3.63M Buy
119,203
+14,141
+13% +$422K 0.13% 99
2013
Q4
$3.05M Buy
105,062
+4,697
+5% +$137K 0.11% 113
2013
Q3
$2.73M Sell
100,365
-6,610
-6% -$180K 0.11% 118
2013
Q2
$2.84M Buy
+106,975
New +$2.96M 0.12% 111

Other funds holding PFE

Johnson Investment Counsel's PFE Position: Q2 2026 in Review

Johnson Investment Counsel reduced its Pfizer (PFE) stake by 5.3% in Q2 2026, selling an estimated $146K and leaving 100,100 shares worth $2.41M. The position accounts for 0.02% of the portfolio, ranked #298.

Johnson Investment Counsel first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $11.6M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Johnson Investment Counsel held 100,100 shares of Pfizer worth $2.41M as of Q2 2026.
  • Johnson Investment Counsel sold 5,581 Pfizer shares in Q2 2026, an estimated $146K.
  • Pfizer made up 0.02% of Johnson Investment Counsel's portfolio in Q2 2026, its #298 holding.
  • Johnson Investment Counsel first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Johnson Investment Counsel's Pfizer position peaked at $11.6M in Q4 2021.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Johnson Investment Counsel's 13F filing for Q2 2026, filed 23 Jul 2026.